JPM Day 2: Obesity’s Volume vs. Value Moment

Day 2 of the J.P. Morgan Healthcare Conference crystallized two themes that will define biopharma strategy for the next decade. Eli Lilly formalized a volume-over-margin approach to obesity with a confirmed $149 cash-pay price point for orforglipron, while AbbVie established what amounts to a new regulatory currency: domestic manufacturing investment in exchange for tariff exemptions and pricing flexibility. The question is no longer just “What’s in your pipeline?” but “What’s your license to operate?”

These developments mark a shift from the innovation-first narrative that has dominated healthcare conferences since the biotech boom. In 2026, capital allocation decisions are being driven as much by commercial strategy and policy positioning as by Phase 3 readouts. The presentations on Tuesday made clear that Big Pharma has absorbed the lesson: the path to sustainable growth runs through Washington as much as through clinical trial enrollment.

Obesity Strategies Diverge: Volume vs. Premium

The contrast between Eli Lilly and Novo Nordisk presentations was striking. In back-to-back sessions, the two obesity market leaders articulated fundamentally different commercial visions for a market that both companies acknowledge will exceed $100 billion annually within the decade.

Lilly executives confirmed orforglipron as a mass-market maintenance therapy, with the lowest dose available at $149 through LillyDirect upon FDA approval. The oral GLP-1, currently under priority review with a decision expected by March 2026, is positioned as a “maintenance backbone” for patients who have achieved target weight loss on injectable therapies. The pricing strategy is explicitly designed to commoditize the decades-long maintenance phase of obesity treatment, prioritizing patient volume over per-unit margin.

The Step-Down Model Takes Shape

The commercial logic is increasingly clear: “Injectable Induction → Oral Maintenance” is emerging as the only viable economic model for long-term payer coverage. This step-down framework—high-efficacy injectable therapy to achieve target weight loss, followed by transition to lower-cost oral maintenance for decades of duration—solves the fundamental unit economics problem that has plagued obesity coverage negotiations. Lilly is betting that patients who achieve meaningful weight loss on Zepbound or Mounjaro will transition to orforglipron for long-term maintenance, creating a closed-loop patient journey that maximizes lifetime value while minimizing per-patient cost at the maintenance phase.

Novo Nordisk, by contrast, defended CagriSema as a high-touch, high-efficacy option for patients who do not respond adequately to single-agent therapy. Leadership used Q&A sessions to address bearish sentiment on CagriSema’s efficacy data, attributing “low-to-mid teens” weight loss percentages in diabetic populations to background medication noise rather than an efficacy ceiling. The message: Novo is fighting for the induction phase with a premium-priced combination injectable, while Lilly is building infrastructure to own the maintenance phase at scale.

The LillyDirect Bypass

Lilly’s validation of the $149 price point via LillyDirect represents more than a pricing decision—it’s a strategic bypass of the traditional rebate structure. By pricing orforglipron below many insurance deductible thresholds, Lilly effectively creates a direct-to-consumer channel that forces payers to cover the drug on lower formulary tiers to avoid losing visibility on patient data and utilization patterns.

For PBMs negotiating 2027 contracts, the $149 anchor will likely accelerate step-therapy protocols that position oral GLP-1s as first-line maintenance therapy. The commercial implications extend far beyond Lilly: any competitor entering the oral obesity market will now be benchmarked against this price point.

AbbVie’s $100 Billion Pledge: The New Policy Currency

AbbVie announced a voluntary agreement with the Trump administration to invest $100 billion in U.S.-based research, development, and manufacturing over the next decade. In exchange, the company secured a three-year exemption from tariffs and future pricing mandates, with commitments to provide lower prices through Medicaid and direct-to-consumer sales via TrumpRx.

The deal, announced Monday evening, sets a new operational baseline for Big Pharma in 2026. Domestic manufacturing investment is now a strategic currency used to secure regulatory stability. At $100 billion, AbbVie’s commitment far exceeds the pledges of its peers: Johnson & Johnson announced $55 billion in March 2025 (with additional commitments since), while AstraZeneca committed $50 billion last July.

The Framework for Avoiding Tariffs

The AbbVie agreement addresses the Trump administration’s “most-favored nation” pricing initiative, which has pressured pharmaceutical companies to align U.S. prices with those in peer countries. The deal includes commitments to expand direct-to-patient offerings through TrumpRx—a government-backed online platform expected to launch this month that allows Americans to purchase medications directly from pharmaceutical manufacturers at substantial discounts, bypassing traditional pharmacy and PBM intermediaries. AbbVie will offer widely used medicines including Humira, Synthroid, Alphagan, and Combigan through the platform.

TrumpRx represents a structural shift in how drugs reach cash-pay patients. By enabling direct manufacturer-to-consumer sales at negotiated prices, the platform creates a parallel distribution channel that sidesteps the rebate-driven pricing complexity of the traditional supply chain. For patients with high deductibles or inadequate coverage, it offers a price-transparent alternative. For manufacturers, participation is now effectively a prerequisite for regulatory accommodation.

For industry watchers, the precedent is clear. Companies that can demonstrate substantial domestic manufacturing investment will receive regulatory flexibility; those that cannot will face tariff exposure. The question now is whether Pfizer, Regeneron, and other holdouts will announce similar packages before the conference concludes.

Executives should note that further terms of the AbbVie agreement remain confidential—the full scope of pricing concessions and investment timelines has not been disclosed. What is clear is that domestic CapEx has become as strategically important as pipeline depth in determining a company’s competitive position.

Private Capital Returns to Obesity Innovation

While public markets remain choppy, private capital is aggressively funding “third generation” obesity assets designed to address the durability and tolerability limitations of current therapies.

Alveus Therapeutics emerged from stealth on January 8, 2026, with a $159.8 million Series A led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds. Sanofi Capital also participated. The financing will support Phase 2 development of ALV-100, a bifunctional GIPR antagonist/GLP-1R agonist designed for durable weight management with improved quality of weight loss, as well as IND filings for amylin-based pipeline candidates.

The mechanism is notable: ALV-100 activates GLP-1 while blocking GIP, a strategy similar to Amgen’s MariTide. The Alveus approach targets the muscle-loss and tolerability issues that continue to challenge the current Lilly/Novo duopoly. CEO Raj Kannan, formerly of I-Mab, has assembled leadership from Novo Nordisk and Eli Lilly, signaling that experienced metabolic drug developers see differentiated opportunity beyond the current generation of therapies.

For venture investors, the Alveus financing represents a thesis on market segmentation: even as Lilly and Novo saturate the broad obesity market, specialized assets addressing specific patient populations—those with lean mass concerns, GI intolerance, or durability challenges—will command premium valuations.

Novartis Doubles Down on Neuroscience

Novartis used JPM to reinforce its commitment to neuroscience through a pair of deals that expand its pipeline in Alzheimer’s disease and radioligand therapy.

The company announced a worldwide licensing and collaboration agreement with SciNeuro Pharmaceuticals for a novel anti-amyloid antibody program. SciNeuro will receive $165 million upfront and is eligible for up to $1.5 billion in development, regulatory, and commercial milestones. The program leverages SciNeuro’s proprietary blood-brain barrier shuttle technology, which is designed to enhance delivery of therapeutic agents to the brain.

The deal positions Novartis to compete in the next generation of Alzheimer’s therapeutics, where shuttle-enabled technologies are emerging as a key differentiator. Current approved treatments—Biogen/Eisai’s Leqembi and Lilly’s Kisunla—have faced uptake challenges related to cost, efficacy, and side effects. A shuttle-enabled approach could potentially deliver more rapid and complete amyloid clearance at lower systemic doses.

Radioligand Pipeline Expansion

Separately, Novartis paid $50 million upfront to license a peptide-based radioligand therapy asset from Zonsen PepLib Biotech, reinforcing its position as the global leader in RLT. The deal follows Novartis’s recent opening of its third U.S. RLT manufacturing facility in Carlsbad, California, and continued investment in the modality that produced Pluvicto and Lutathera.

The PepLib asset complements Novartis’s existing RLT portfolio and builds on the $23 billion U.S. infrastructure investment the company announced in 2025. For oncology executives tracking the radiopharma space, Novartis is systematically building both pipeline depth and manufacturing moat.

Ionis Confirms Commercial Momentum

Ionis Pharmaceuticals confirmed that Tryngolza (olezarsen) generated approximately $105 million in preliminary U.S. net product sales for full-year 2025, hitting the upper end of guidance. The performance validates Ionis’s evolution from an R&D organization to a commercial-stage company.

Tryngolza was approved in December 2024 as the first-ever FDA-approved treatment for familial chylomicronemia syndrome (FCS). CEO Brett Monia characterized the launch as “overwhelmingly positive,” citing patient stories of reduced body pain and fewer hospitalizations for recurrent acute pancreatitis.

The focus now shifts to the sNDA filing for severe hypertriglyceridemia (sHTG), submitted following receipt of Breakthrough Therapy Designation. Phase 3 CORE and CORE2 studies demonstrated placebo-adjusted triglyceride reductions of up to 72% and an 85% reduction in acute pancreatitis events. Ionis has increased its peak sales guidance for olezarsen in sHTG to greater than $2 billion, up from greater than $1 billion previously.

For the competitive landscape in triglyceride therapy, the Ionis guidance sets a high bar. Arrowhead Pharmaceuticals’ Redemplo (plozasiran), approved in November 2025, competes directly for the same patient population. The duopoly’s performance metrics will be closely watched throughout 2026.

Corporate Signals: M&A and Macro

Medtronic: “Capacity for Deals”

Medtronic CEO Geoff Martha signaled that the medtech giant is ready to accelerate tuck-in acquisitions after years of operational improvement. CFO Thierry Piéton told investors that the company has “earned the right” to do acquisitions and has the capacity to “step up” in M&A activity. Any deals would be in the low- to mid-single-digit billion-dollar range and would be “supplemental” to organic growth.

The renewed M&A focus follows activist investor Elliott Investment Management taking a stake in Medtronic and the company’s decision to spin out its diabetes division. For mid-cap cardiovascular and neuromodulation companies, Medtronic’s comments suggest a potential buyer is actively looking.

Thermo Fisher: Stabilization, Not Recovery

Thermo Fisher Scientific reiterated a “stabilization” outlook for its business. Manufacturing contracts (CDMO) are holding up due to reshoring trends, but heavy instrument spending remains muted. The macro signal: research tools demand has not yet rebounded to pre-2022 levels, and biotech customers remain cautious on capital equipment purchases.

Regulatory and Safety Notes

Tolebrutinib Safety Bar

New FDA documents regarding Sanofi’s Complete Response Letter for tolebrutinib (BTK inhibitor for multiple sclerosis) cite “idiosyncratic” liver injury risks. The safety concerns raise the regulatory bar for all chronic oral neurology drugs—a signal that may impact sentiment on follow-on pain assets from Vertex and others pursuing long-term oral therapies in neurological indications.

Bayer’s Diagnose-and-Treat Play

Bayer acquired two diagnostic tracers from Attralus to bolster its cardiac imaging portfolio, signaling a “diagnose-and-treat” strategy for amyloidosis. The deal pairs diagnostic imaging capability with therapeutic development, creating an integrated approach to patient identification and treatment. Combined with Novartis’s radiopharma activity, the move reinforces the thesis that nuclear medicine—both diagnostic and therapeutic—is becoming a competitive battleground requiring end-to-end infrastructure investment.

Today’s Calendar: What to Watch (Day 3)

The JPM calendar for Wednesday, January 14, features several presentations with strategic implications.

Biogen presents at 7:30 AM Pacific Time with expected focus on Leqembi launch metrics in Alzheimer’s disease. The presentation will provide the first detailed look at uptake trends following the September 2025 approval of the subcutaneous formulation.

Intuitive Surgical presents at 9:00 AM, where procedure volume data will serve as a leading indicator for hospital staffing and capital equipment trends. An FDA Commissioner fireside chat at 10:30 AM will address accelerated approval reforms—critical context for companies with therapies moving through conditional approval pathways.

Vertex Pharmaceuticals presents at 1:00 PM with a deep dive on the “Pain Portfolio,” including suzetrigine follow-on programs. The presentation will provide updates on the NaV1.8 pipeline beyond Journavx, including diabetic peripheral neuropathy data that could substantially expand the commercial opportunity.

The Operating License Framework

JPM 2026 is clarifying a new competitive framework for biopharma. Pipeline innovation remains necessary but is no longer sufficient. Companies must now demonstrate three capabilities: scientific excellence, commercial execution, and policy alignment.

Lilly’s $149 price point is a commercial execution play—using direct-to-consumer infrastructure to bypass traditional payer friction. AbbVie’s $100 billion pledge is a policy alignment play—using domestic manufacturing investment to secure regulatory stability. Both represent strategic responses to a market environment where the rules of engagement have fundamentally changed.

For executives navigating the remainder of the conference, the framework is clear: investors are evaluating not just what you’re developing, but how you plan to get it to patients, at what price, and with what manufacturing footprint. The companies that can articulate credible answers to all three questions will command premium valuations. Those that focus on pipeline alone may find the market less forgiving than it was in 2021.

The “license to operate” is no longer a metaphor. It’s a literal requirement, negotiated deal by deal with regulators, payers, and policymakers. AbbVie’s three-year tariff exemption is simply the most explicit version of a dynamic that will define the sector for years to come.

BioMed Nexus provides daily intelligence for leaders in biotech, medtech, and pharma. This editorial deep dive is intended for context, not investment recommendation.